Editas Medicine Stock Current Liabilities

EDIT Stock

USD 2.37 0.04 1.66%

Editas Medicine fundamentals help investors to digest information that contributes to Editas Medicine's financial success or failures. It also enables traders to predict the movement of Editas Stock. The fundamental analysis module provides a way to measure Editas Medicine's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Editas Medicine stock.

Short Long Term Debt Total Total Assets

Non Current Liabilities Total is likely to gain to about 115.2 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 40.9 M in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Editas Medicine Company Current Liabilities Analysis

Editas Medicine's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.

Current Liabilities

Payables

+

Accrued Debt

More About Current Liabilities | All Equity Analysis

Current Editas Medicine Current Liabilities

6.92 M

Most of Editas Medicine's fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Editas Medicine is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Editas Current Liabilities Driver Correlations

Understanding the fundamental principles of building solid financial models for Editas Medicine is extremely important. It helps to project a fair market value of Editas Stock properly, considering its historical fundamentals such as Current Liabilities. Since Editas Medicine's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Editas Medicine's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Editas Medicine's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Property Plant Equipment	Net Tangible Assets	Current Deferred Revenue	Long Term Debt	Net Receivables	Deferred Long Term Liab	Short Long Term Debt	Short Term Debt	Common Stock	Short Term Investments	Capital Surpluse	Long Term Debt Total	Net Invested Capital	Net Working Capital	Long Term Investments	Capital Stock
Total Assets		0.95	-0.81	-0.83	0.86	0.75	0.99	0.61	0.95	0.66	0.85	0.38	0.93	0.75	0.85	0.8	0.96	0.92	-0.66	0.78	0.6	0.75	0.65
Total Stockholder Equity	0.95		-0.81	-0.83	0.82	0.51	0.91	0.5	1.0	0.59	0.68	0.39	0.86	0.58	0.82	0.84	0.93	0.93	-0.63	0.87	0.62	0.83	0.72
Net Debt	-0.81	-0.81		0.57	-0.7	-0.52	-0.84	-0.81	-0.8	-0.87	-0.66	-0.09	-0.73	-0.58	-0.52	-0.49	-0.76	-0.68	0.45	-0.53	-0.63	-0.41	-0.34
Retained Earnings	-0.83	-0.83	0.57		-0.87	-0.54	-0.77	-0.36	-0.85	-0.41	-0.67	-0.78	-0.88	-0.6	-0.89	-0.93	-0.8	-0.94	0.9	-0.77	-0.21	-0.85	-0.92
Accounts Payable	0.86	0.82	-0.7	-0.87		0.64	0.82	0.57	0.85	0.61	0.78	0.55	0.86	0.7	0.87	0.82	0.79	0.91	-0.68	0.59	0.23	0.7	0.71
Total Liab	0.75	0.51	-0.52	-0.54	0.64		0.81	0.63	0.52	0.57	0.89	0.24	0.77	0.87	0.61	0.41	0.67	0.55	-0.49	0.31	0.34	0.3	0.27
Total Current Assets	0.99	0.91	-0.84	-0.77	0.82	0.81		0.69	0.9	0.71	0.86	0.29	0.94	0.78	0.78	0.7	0.95	0.85	-0.63	0.7	0.63	0.63	0.54
Property Plant Equipment	0.61	0.5	-0.81	-0.36	0.57	0.63	0.69		0.5	0.86	0.72	-0.02	0.66	0.69	0.38	0.18	0.56	0.41	-0.38	0.09	0.27	0.02	0.05
Net Tangible Assets	0.95	1.0	-0.8	-0.85	0.85	0.52	0.9	0.5		0.59	0.7	0.44	0.87	0.6	0.85	0.87	0.93	0.96	-0.67	0.86	0.57	0.84	0.76
Current Deferred Revenue	0.66	0.59	-0.87	-0.41	0.61	0.57	0.71	0.86	0.59		0.68	0.11	0.62	0.66	0.39	0.26	0.58	0.47	-0.38	0.28	0.4	0.23	0.12
Long Term Debt	0.85	0.68	-0.66	-0.67	0.78	0.89	0.86	0.72	0.7	0.68		0.31	0.82	0.98	0.82	0.57	0.71	0.71	-0.54	0.47	0.31	0.49	0.47
Net Receivables	0.38	0.39	-0.09	-0.78	0.55	0.24	0.29	-0.02	0.44	0.11	0.31		0.54	0.29	0.57	0.69	0.38	0.59	-0.84	0.45	-0.3	0.68	0.8
Deferred Long Term Liab	0.93	0.86	-0.73	-0.88	0.86	0.77	0.94	0.66	0.87	0.62	0.82	0.54		0.73	0.81	0.76	0.94	0.87	-0.83	0.65	0.36	0.66	0.66
Short Long Term Debt	0.75	0.58	-0.58	-0.6	0.7	0.87	0.78	0.69	0.6	0.66	0.98	0.29	0.73		0.77	0.48	0.59	0.61	-0.49	0.4	0.24	0.41	0.41
Short Term Debt	0.85	0.82	-0.52	-0.89	0.87	0.61	0.78	0.38	0.85	0.39	0.82	0.57	0.81	0.77		0.9	0.74	0.92	-0.68	0.75	0.25	0.82	0.85
Common Stock	0.8	0.84	-0.49	-0.93	0.82	0.41	0.7	0.18	0.87	0.26	0.57	0.69	0.76	0.48	0.9		0.76	0.96	-0.75	0.83	0.3	0.92	0.95
Short Term Investments	0.96	0.93	-0.76	-0.8	0.79	0.67	0.95	0.56	0.93	0.58	0.71	0.38	0.94	0.59	0.74	0.76		0.87	-0.7	0.76	0.6	0.71	0.61
Capital Surpluse	0.92	0.93	-0.68	-0.94	0.91	0.55	0.85	0.41	0.96	0.47	0.71	0.59	0.87	0.61	0.92	0.96	0.87		-0.73	0.81	0.4	0.87	0.87
Long Term Debt Total	-0.66	-0.63	0.45	0.9	-0.68	-0.49	-0.63	-0.38	-0.67	-0.38	-0.54	-0.84	-0.83	-0.49	-0.68	-0.75	-0.7	-0.73		-0.59	-0.06	-0.66	-0.78
Net Invested Capital	0.78	0.87	-0.53	-0.77	0.59	0.31	0.7	0.09	0.86	0.28	0.47	0.45	0.65	0.4	0.75	0.83	0.76	0.81	-0.59		0.61	0.93	0.8
Net Working Capital	0.6	0.62	-0.63	-0.21	0.23	0.34	0.63	0.27	0.57	0.4	0.31	-0.3	0.36	0.24	0.25	0.3	0.6	0.4	-0.06	0.61		0.34	0.1
Long Term Investments	0.75	0.83	-0.41	-0.85	0.7	0.3	0.63	0.02	0.84	0.23	0.49	0.68	0.66	0.41	0.82	0.92	0.71	0.87	-0.66	0.93	0.34		0.91
Capital Stock	0.65	0.72	-0.34	-0.92	0.71	0.27	0.54	0.05	0.76	0.12	0.47	0.8	0.66	0.41	0.85	0.95	0.61	0.87	-0.78	0.8	0.1	0.91

Click cells to compare fundamentals

Editas Current Liabilities Historical Pattern

Today, most investors in Editas Medicine Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Editas Medicine's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Editas Medicine current liabilities as a starting point in their analysis.

Editas Medicine Current Liabilities

Timeline

Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.

Competition

Predict Editas Medicine

Total Current Liabilities Over Time

Editas Total Current Liabilities

Total Current Liabilities

40.93 Million

At this time, Editas Medicine's Total Current Liabilities is comparatively stable compared to the past year.

In accordance with the recently published financial statements, Editas Medicine has a Current Liabilities of 6.92 M. This is 99.6% lower than that of the Biotechnology sector and 98.72% lower than that of the Health Care industry. The current liabilities for all United States stocks is 99.91% higher than that of the company.

Editas Medicine Current Valuation Drivers

We derive many important indicators used in calculating different scores of Editas Medicine from analyzing Editas Medicine's financial statements. These drivers represent accounts that assess Editas Medicine's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Editas Medicine's important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	1.5B	4.1B	1.8B	609.1M	769.5M	1.0B
Enterprise Value	1.3B	4.0B	1.6B	511.5M	682.4M	921.9M

Editas Medicine ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Editas Medicine's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Editas Medicine's managers, analysts, and investors.

Environmental

Governance

Social

Editas Fundamentals

	Return On Equity	-0.79
	Return On Asset	-0.34
	Current Valuation	(27.66 M)
	Shares Outstanding	82.55 M
	Shares Owned By Insiders	0.32 %
	Shares Owned By Institutions	70.11 %
	Number Of Shares Shorted	17.24 M
	Price To Earning	(7.02) X
	Price To Book	1.13 X
	Price To Sales	3.22 X
	Revenue	78.12 M
	Gross Profit	(155.25 M)
	EBITDA	(163.12 M)
	Net Income	(153.22 M)
	Cash And Equivalents	452.56 M
	Cash Per Share	6.59 X
	Total Debt	36.54 M
	Debt To Equity	0.04 %
	Current Ratio	12.67 X
	Book Value Per Share	2.13 X
	Cash Flow From Operations	(132.18 M)
	Short Ratio	8.76 X
	Earnings Per Share	(2.54) X
	Target Price	9.07
	Number Of Employees	265
	Beta	2.01
	Market Capitalization	198.94 M
	Total Asset	499.15 M
	Retained Earnings	(1.23 B)
	Working Capital	277.61 M
	Current Asset	144.99 M
	Current Liabilities	6.92 M
	Net Asset	499.15 M

About Editas Medicine Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Editas Medicine's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Editas Medicine using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Editas Medicine based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Editas Stock Analysis

When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC